Cullinan Therapeutics, Inc.

The current price of CGEM is $10.80 — it has decreased by 13.53% since the previous close. Data as of Nov 5, 2026.

CGEM is down 29.78% over the past week, down 32.67% over the past month and up 47.74% over the past year. The price is below its 200-day moving average of $15.86.

Analysts' average 12-month price target for CGEM is $35.00, which implies 224.07% upside from the current price. Individual estimates range from $27.00 to $41.00.

Of the 12 analysts covering Cullinan Therapeutics, Inc., 1 rates it a strong buy and 11 rate it a buy. The overall consensus is bullish. Analyst ratings are opinions and do not guarantee future performance.

Cullinan Therapeutics, Inc. has a market capitalization of $663.75M. The company belongs to the Healthcare sector. Compare it with other companies in the stock screener.

In its most recent quarterly report, Cullinan Therapeutics, Inc. posted a loss of $0.81 per share against an estimate of -$0.7993, missing expectations by 1.34%. Upcoming reports are listed in the earnings calendar.

Cullinan Therapeutics, Inc. has not paid any dividends over the past year.

Companies most comparable to Cullinan Therapeutics, Inc. include Legend Biotech Corporation, Xencor, Inc., Nurix Therapeutics, Inc., Janux Therapeutics, Inc. and Immatics N.V.

In the latest trading session CGEM moved between $10.77 and $12.48, a range of 15.79% of its current price.

Investing in stocks requires thorough research: study the company's financials, related news and technical analysis before making a decision. Technical analysis of Cullinan Therapeutics, Inc. shows a strong sell rating today and a strong sell rating on the weekly timeframe. Market conditions change quickly, so it is worth looking further ahead as well — the 1-month rating for Cullinan Therapeutics, Inc. is sell. Technical ratings are indicators, not investment advice.

Over the past 52 weeks CGEM has traded between $6.73 and $23.19. The current price is 53.43% below its 52-week high.